Key statistics
On Friday, Heron Therapeutics Inc (0J4V:LSE) closed at 1.10, 3.94% above its 52-week low of 1.05, set on Nov 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 1.10 |
Low | 1.10 |
Bid | -- |
Offer | -- |
Previous close | 1.08 |
Average volume | 11.31k |
---|---|
Shares outstanding | 152.09m |
Free float | 151.01m |
P/E (TTM) | -- |
Market cap | 162.74m USD |
EPS (TTM) | -0.1841 USD |
Data delayed at least 20 minutes, as of Nov 22 2024 15:51 GMT.
More ▼
Press releases
- Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
- Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
- Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
- Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
- Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
More ▼